Published on September 21, 2009 at 8:30 AM
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has received a request for proposal (RFP) from the U.S. Department of Health & Human Services (HHS) for the supply of intravenous (i.v) peramivir for the treatment of critically ill influenza patients under Emergency Use Authorization (EUA).
The RFP indicates that the minimum and maximum order quantities to be ordered by the government are 1,000 and 40,000 courses of anti-viral treatment. The RFP specifies that BioCryst would also be required to maintain the ability to manufacture additional treatment courses dependent on the volume and size of anti-viral orders received from HHS for additional needs for either treatment or prophylaxis. The current RFP process may or may not result in a government order for peramivir and does not guarantee issuance of an EUA.
BioCryst management is preparing a response to the RFP and intends to provide an update once the process has reached a conclusion.
Source: http://www.biocryst.com
00ebe76b-dca8-4e3b-88fd-167aa08dfdb0|0|.0
Posted in: Disease/Infection News | Pharmaceutical News
Tags: Biotechnology, Burn, Cancer, Cell, H1N1, Health and Human Services, Influenza, Lymphoma, Pandemic, Prophylaxis, Swine Flu